Literature DB >> 24535052

β-Elemene inhibits the metastasis of B16F10 melanoma cells by downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9.

Hong Shi1, Lei Liu, Limin Liu, Jin Geng, Yun Zhou, Lei Chen.   

Abstract

β-Elemene has been reported to be effective for the treatment of leukemia and certain solid tumors in basic and clinical studies. However, the mechanism of action of this phytochemical remains unknown. This study aimed to investigate the effect and mechanism of β-elemene in the mouse melanoma cell line B16F10. Cell viability was measured using the MTT assay. β-Elemene inhibited B16F10 melanoma cell metastasis, examined using scratch and Transwell migration/invasion assays. The mRNA and protein expression of urokinase-type plasminogen activator (uPA), the uPA receptor (uPAR), matrix metalloproteinase (MMP)-2, and MMP-9 were assayed using real-time PCR, immunocytochemistry, and western blotting methods. The results indicated that β-elemene inhibited the viability of B16F10 melanoma cells in a dose-dependent and time-dependent manner. The migratory and invasive capacities of B16F10 cells were also inhibited by β-elemene. The expression of uPA, uPAR, MMP-2, and MMP-9 was reduced by β-elemene at both the mRNA and protein level. β-Elemene inhibits the metastasis of B16F10 melanoma cells through downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9. Thus, β-elemene is a natural potential anticancer drug.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24535052     DOI: 10.1097/CMR.0000000000000043

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  18 in total

1.  Premature rupture of the fetal membrane combined with subclinical chorioamnionitis negatively affects pregnancy outcomes by a mechanism associated with reduced levels of matrix metalloproteinase-2.

Authors:  Hongli Zhang; L U Wang; Jing Wang; Jiangrong Hei; Cailian Ruan
Journal:  Exp Ther Med       Date:  2015-06-10       Impact factor: 2.447

2.  Demethylation effects of elemene on the GSTP1 gene in HCC cell line QGY7703.

Authors:  Baoqiang Wu; Yong Jiang; Feng Zhu; Donglin Sun; Hongjun Huang
Journal:  Oncol Lett       Date:  2016-02-18       Impact factor: 2.967

3.  Elemene injection induced autophagy protects human hepatoma cancer cells from starvation and undergoing apoptosis.

Authors:  Yan Lin; Keming Wang; Chunping Hu; Lin Lin; Shukui Qin; Xueting Cai
Journal:  Evid Based Complement Alternat Med       Date:  2014-07-24       Impact factor: 2.629

Review 4.  Long non-coding RNAs in cutaneous melanoma: clinical perspectives.

Authors:  Eva Hulstaert; Lieve Brochez; Pieter-Jan Volders; Jo Vandesompele; Pieter Mestdagh
Journal:  Oncotarget       Date:  2017-06-27

5.  MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA.

Authors:  Rossella Salemi; Luca Falzone; Gabriele Madonna; Jerry Polesel; Diana Cinà; Domenico Mallardo; Paolo A Ascierto; Massimo Libra; Saverio Candido
Journal:  Front Pharmacol       Date:  2018-08-14       Impact factor: 5.810

6.  Elemene inhibits the migration and invasion of 4T1 murine breast cancer cells via heparanase.

Authors:  Yi Zhang; Xu Sun; Nan Nan; Ke-Xin Cao; Cong Ma; Guo-Wang Yang; Ming-Wei Yu; Lin Yang; Jin-Ping Li; Xiao-Min Wang; Gan-Lin Zhang
Journal:  Mol Med Rep       Date:  2017-05-26       Impact factor: 2.952

7.  Exploring the Mechanism of Flaccidoxide-13-Acetate in Suppressing Cell Metastasis of Hepatocellular Carcinoma.

Authors:  Yu-Jen Wu; Wen-Chi Wei; Guo-Fong Dai; Jui-Hsin Su; Yu-Hwei Tseng; Tsung-Chang Tsai
Journal:  Mar Drugs       Date:  2020-06-15       Impact factor: 5.118

8.  Bornyl cis-4-Hydroxycinnamate Suppresses Cell Metastasis of Melanoma through FAK/PI3K/Akt/mTOR and MAPK Signaling Pathways and Inhibition of the Epithelial-to-Mesenchymal Transition.

Authors:  Tzu-Yen Yang; Mei-Li Wu; Chi-I Chang; Chih-I Liu; Te-Chih Cheng; Yu-Jen Wu
Journal:  Int J Mol Sci       Date:  2018-07-24       Impact factor: 5.923

Review 9.  Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy.

Authors:  Bingtao Zhai; Yiying Zeng; Zhaowu Zeng; Nana Zhang; Chenxi Li; Yijun Zeng; Yu You; Shuling Wang; Xiabin Chen; Xinbing Sui; Tian Xie
Journal:  Int J Nanomedicine       Date:  2018-10-10

10.  Nuclear DLC1 exerts oncogenic function through association with FOXK1 for cooperative activation of MMP9 expression in melanoma.

Authors:  Xintao Yang; Feng Hu; Jessica Aijia Liu; Shan Yu; May Pui Lai Cheung; Xuelai Liu; Irene Oi-Lin Ng; Xin-Yuan Guan; Kelvin K W Wong; Rakesh Sharma; Hong Lok Lung; Yufei Jiao; Leo Tsz On Lee; Martin Cheung
Journal:  Oncogene       Date:  2020-03-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.